Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793395 | 0.97 | MEN1 (0.65) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL8794066 | 0.91 | MEN1 (0.82) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL26326700 | 0.86 | CA12 (0.60) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL29870275 | 0.84 | L3MBTL1 (0.77) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL6882887 | 0.84 | L3MBTL1 (0.77) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL4126119 | 0.82 | AKR1C3 (0.55) | MEN1KMT2AHTTENPP2CA2 | |
| SCHEMBL22558454 | 0.82 | AKR1C3 (0.55) | MEN1KMT2AHTTENPP2CA2 | |
| SCHEMBL4950633 | 0.82 | MEN1 (0.70) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL16904608 | 0.82 | MEN1 (0.70) | MEN1KMT2AL3MBTL1TDP1HTT | |
| SCHEMBL26326698 | 0.81 | L3MBTL1 (0.71) | MEN1KMT2AL3MBTL1TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| EP-1827427-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| EP-1824480-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-08-29 | — | — | EP | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| WO-2006061376-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL D0PAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061377-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2A, HTR2C, HTR1A | MEN1 4432/4885KMT2A 520/4885L3MBTL1 3499/4885 |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | MEN1 4445/4885KMT2A 1978/4885L3MBTL1 4190/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | MEN1 4445/4885KMT2A 1978/4885L3MBTL1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.